UNITED STATES SECURITIES AND EXCHANGE COMMISSION Form 144 Filer Information Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES

PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001782163 Filer CCC XXXXXXXX Is this a LIVE or TEST Filing? LIVE TEST

Submission Contact Information

Name Phone

E-Mail Address

144: Issuer Information

Name of Issuer Mersana Therapeutics, Inc.

SEC File Number 001-38129

840 Memorial Drive

Cambridge Address of Issuer

MASSACHUSETTS

02139

617-498-0020 Phone

Name of Person for Whose Account the Securities are To Be Sold Brian DeSchuytner

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Officer Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market		Approximate Date of Sale	SACHIPITIAG
Common Stock	ETRADE Financial Corporation 3 Edison Drive Alpharetta GA 30005	8470	5166.70	124027229	01/16/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the	Date you	Nature of	Name of	Is	Date	Amount of	Date of	Nature of
Class	Acquired	Acquisition	Person from	this	Donor	Securities	Payment	Payment *
	_	Transaction			Acquired	Acquired		

	Whom Acquired	a Gift?		
Vesting of Common Stock 01/15/2025 restricted stock unit grant	Issuer		6250	01/15/2025 Services rendered
Vesting of Common Stock 01/15/2025 restricted stock unit grant	Issuer		14583	01/15/2025 Services rendered

^{*} If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Brian DeSchuytner c/o Mersana Therapeutics, Inc. 840 Memorial Drive Cambridge MA 02139	Common Stock	01/15/2025	2331	1468.53
Brian DeSchuytner c/o Mersana Therapeutics, Inc. 840 Memorial Drive Cambridge MA 02139	Common Stock	01/14/2025	3713	2450.58

144: Remarks and Signature

Remarks (1) Aggregate market value based on the closing price per share on Nasdaq on

January 16, 2025. (2) Shares outstanding as of January 16, 2025.

Date of Notice 01/17/2025

Date of Plan Adoption or Giving of

Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ Alejandra Carvajal, as attorney-in-fact for Brian DeSchuytner

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)